Sources and References

Primary textbook — Tisdale JE, Miller DA. Drug-Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018. Online resources — FDA MedWatch adverse event reporting system; Health Canada MedEffect Canada vigilance program; WHO VigiAccess; Lexicomp adverse drug reactions database; Micromedex adverse effects documentation; Clinical Pharmacology drug safety summaries

Chapter 1: Conceptual Foundations of Drug-Induced Disease

What Is Drug-Induced Disease?

Every drug capable of producing therapeutic benefit is also capable, under the right conditions and in the right patient, of producing harm. The history of pharmacology is inseparable from the history of iatrogenic — physician-caused — injury, and a pharmacist who does not take drug-induced disease seriously is not yet practising at the level the profession demands. This course builds the clinical knowledge and reasoning skills required to recognize when a drug is causing disease, to understand why it does so, to prevent such harm when possible, and to manage it when it occurs.

Drug-induced disease refers to pathological processes caused by or significantly contributed to by a medication, whether prescription, nonprescription, or natural health product. The scope is vast: essentially every organ system can be affected, virtually every drug class carries some risk, and drug-induced diseases collectively contribute substantially to morbidity, mortality, and healthcare costs. Population-based studies consistently identify adverse drug reactions as a leading cause of hospital admissions in Canada — estimates range from 2% to 12% of all hospital admissions being drug-related — and in-hospital adverse drug events cause substantial patient harm and prolonged length of stay.

A conceptual framework for drug-induced disease requires distinguishing type A from type B adverse drug reactions. Type A reactions are dose-related, pharmacologically predictable extensions of the drug’s known mechanisms. They represent the majority of adverse drug reactions and are in principle detectable from pharmacokinetic and pharmacodynamic principles. They are managed by dose reduction, discontinuation, or selection of an alternative agent with a different mechanism. Type B reactions are idiosyncratic — unexpected, dose-independent, and not predictable from standard pharmacology. They include immune-mediated reactions (ranging from urticaria to anaphylaxis to organ-specific immune injury) and pharmacogenomically determined susceptibilities (such as glucose-6-phosphate dehydrogenase deficiency-associated hemolytic anemia with certain oxidizing drugs). Type B reactions are often unpredictable at the individual level but can be anticipated at the population level through pharmacovigilance and genetic screening programs.

The systematic approach to a patient case in drug-induced disease follows the pharmacist’s patient care process — collect, assess, plan, implement, follow up — with specific emphasis on: constructing a complete medication exposure timeline; identifying the temporal relationship between drug initiation and symptom onset; applying causality assessment tools; developing a monitoring plan for detection of drug-induced toxicity before it causes clinically overt disease; and constructing a management plan that may include dose reduction, drug discontinuation, and specific antidotal or supportive therapy.

Chapter 2: Drug-Induced Hematologic Disorders

Overview of Hematotoxicity

The hematopoietic system — producing approximately 200 billion new red blood cells, 10 billion white blood cells, and 400 billion platelets daily from a relatively small pool of pluripotent stem cells in the bone marrow — is uniquely vulnerable to drug injury. The high replicative rate of hematopoietic progenitors makes them particularly susceptible to agents that interfere with DNA synthesis or mitotic division. The differentiated cells of the blood — erythrocytes, leukocytes, platelets — can also be directly injured by drugs or by drug-induced immune mechanisms.

Drug-Induced Anemia

Aplastic anemia is a potentially life-threatening condition characterized by pancytopenia (reduction in all cell lines) resulting from destruction or suppression of hematopoietic stem cells. Drug-induced aplastic anemia accounts for approximately 15% to 25% of aplastic anemia cases. The classic offending agents include chloramphenicol (dose-independent idiosyncratic aplasia that historically affected approximately 1 in 30,000 treated patients), carbamazepine, phenytoin, sulfonamides, gold salts, and NSAIDs. Chloramphenicol can also produce a dose-dependent, reversible bone marrow suppression distinct from the idiosyncratic aplasia.

Drug-induced hemolytic anemia results from drug-mediated destruction of erythrocytes, which may be immune-mediated or non-immune-mediated. The most clinically important non-immune mechanism involves drugs that produce oxidative stress in erythrocytes — generating reactive oxygen species that overwhelm the cell’s antioxidant defenses and oxidize hemoglobin to methemoglobin (which cannot carry oxygen) or cause precipitation of denatured hemoglobin as Heinz bodies that mark erythrocytes for destruction by splenic macrophages. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency — an X-linked enzymatic disorder affecting approximately 400 million people globally, with highest prevalence in populations from sub-Saharan Africa, the Mediterranean basin, the Middle East, and Southeast Asia — are exquisitely vulnerable to oxidative hemolysis because G6PD is required for the pentose phosphate pathway that regenerates glutathione, the cell’s primary antioxidant defense. Drugs that precipitate hemolysis in G6PD-deficient individuals include primaquine, rasburicase, dapsone, nitrofurantoin, methylene blue, and at very high doses, aspirin and vitamin C.

Immune-mediated hemolytic anemia involves drug-dependent antibody formation: the drug (or its metabolite) binds to the erythrocyte surface and serves as a hapten that triggers antibody production, or it induces autoantibody formation against native red cell antigens. Methyldopa classically induces autoimmune hemolytic anemia through the latter mechanism; it produces a positive direct antiglobulin test (Coombs test) in 10% to 20% of patients taking it long-term, with overt hemolytic anemia developing in a smaller fraction. Penicillin produces hemolytic anemia via the hapten mechanism when given in very high doses — the drug binds covalently to the erythrocyte membrane, stimulating IgG antibody production directed against penicillin-coated cells.

Drug-Induced Thrombocytopenia

Drug-induced thrombocytopenia (DIT) is a reduction in platelet count caused by a drug, either through decreased platelet production (bone marrow suppression by cytotoxic chemotherapy) or increased platelet destruction, primarily through immune mechanisms. Immune-mediated DIT occurs when drug-dependent antibodies bind to drug-platelet or drug-glycoprotein complexes on the platelet surface, targeting platelets for destruction by the reticuloendothelial system. The platelet nadir typically occurs 5 to 14 days after drug initiation (on primary exposure, allowing time for antibody development) or within hours on rechallenge.

Heparin-induced thrombocytopenia (HIT) is the most clinically important form of drug-induced thrombocytopenia because, paradoxically, it causes thrombosis rather than just bleeding. In HIT type II (the clinically significant form), unfractionated heparin (and to a lesser degree, low molecular weight heparin) forms complexes with platelet factor 4 (PF4), a protein released from activated platelets, generating a neo-antigen that triggers IgG antibody formation in susceptible patients. The resulting antibody-heparin-PF4 complex activates platelets through Fc receptors, producing intense platelet aggregation, microthrombi, and paradoxical thrombotic events (deep vein thrombosis, pulmonary embolism, arterial thrombosis, limb-threatening thrombosis) despite thrombocytopenia. HIT occurs in approximately 1% to 3% of patients receiving unfractionated heparin for more than 4 days. The 4Ts score — assessing Thrombocytopenia (magnitude), Timing (typical 5 to 10 days after heparin initiation), Thrombosis or other sequelae, and other explanations for Thrombocytopenia — provides a validated clinical probability score. Management requires immediate cessation of all heparin products and initiation of an alternative anticoagulant (argatroban, bivalirudin, or fondaparinux).

Drug-Induced Neutropenia and Agranulocytosis

Drug-induced neutropenia — reduction in absolute neutrophil count below 1.5 × 10⁹/L — and its severe form agranulocytosis (ANC < 0.5 × 10⁹/L) expose patients to life-threatening bacterial and fungal infections. The most dangerous manifestation is febrile neutropenia — fever in a patient with severe neutropenia — which carries substantial mortality without prompt antibiotic therapy. Causative agents include antithyroid drugs (carbimazole, propylthiouracil — affecting approximately 0.3% to 0.6% of users), clozapine (agranulocytosis in approximately 1% to 2% of patients, necessitating mandatory absolute neutrophil count monitoring under a risk management program), antipsychotics (notably clozapine), sulfonamides, procainamide, and many chemotherapy agents.

Chapter 3: Drug-Induced Acid-Base Disorders

Physiologic Regulation of Acid-Base Balance

The human body maintains arterial blood pH within a remarkably narrow range — 7.35 to 7.45 — through an integrated regulatory system involving pulmonary CO₂ excretion, renal bicarbonate reabsorption and acid excretion, and chemical buffering by bicarbonate, hemoglobin, and plasma proteins. Disruption of any of these regulatory mechanisms by a drug can produce clinically significant acid-base disturbance.

The four primary acid-base disorders — metabolic acidosis, metabolic alkalosis, respiratory acidosis, and respiratory alkalosis — are each characterized by specific changes in arterial blood gas parameters (pH, PaCO₂, HCO₃⁻) and are accompanied by predictable compensatory responses that partially normalize the pH but are incapable of returning it to the normal range on their own.

Drug-Induced Metabolic Acidosis

Metabolic acidosis is characterized by a reduction in serum bicarbonate concentration (< 22 mEq/L) and a compensatory decrease in PaCO₂ through hyperventilation (Kussmaul breathing). The anion gap (AG = Na⁺ − [Cl⁻ + HCO₃⁻]; normal 8 to 12 mEq/L) helps classify metabolic acidosis into high anion gap (where unmeasured anions accumulate in the plasma) and normal anion gap (hyperchloremic) varieties.

Drug-induced high anion gap metabolic acidosis arises from accumulation of organic acid anions. The mnemonic MUDPILES enumerates classic causes including methanol (metabolized to formic acid) and ethylene glycol (metabolized to glycolic and oxalic acids) — both of which are toxic alcohol ingestions rather than therapeutic drug use, but represent important toxicological applications of the anion gap framework. Therapeutically relevant causes include propylene glycol (the carrier solvent in many intravenous drug formulations including lorazepam, diazepam, and phenobarbital infusions) that accumulates to toxic levels in patients receiving prolonged high-dose infusions; metformin-associated lactic acidosis (MALA) — a rare but potentially fatal complication of metformin particularly in patients with conditions that impair hepatic lactate clearance (acute kidney injury, liver failure, hypoxemia, excessive alcohol use); nucleoside reverse transcriptase inhibitors (NRTIs) such as stavudine and didanosine that cause mitochondrial toxicity and lactic acidosis through impaired oxidative phosphorylation; and salicylate toxicity, which produces a complex mixed acid-base disorder with early respiratory alkalosis followed by metabolic acidosis as salicylate uncouples oxidative phosphorylation.

Drug-Induced Respiratory Acidosis and Alkalosis

Respiratory acidosis — elevation of PaCO₂ above 45 mmHg with consequent decrease in pH — can be produced by any drug that depresses central respiratory drive or impairs the mechanical act of breathing. Opioids reduce the sensitivity of respiratory centre neurons to CO₂, producing dose-dependent hypoventilation that is the mechanism of opioid overdose death. Benzodiazepines and other CNS depressants similarly blunt hypercapnic ventilatory drive. The combination of opioids and benzodiazepines produces supra-additive respiratory depression and is responsible for the majority of unintentional opioid overdose deaths.

Respiratory alkalosis — PaCO₂ < 35 mmHg with consequent increase in pH — results from drug-induced hyperventilation. Salicylate toxicity in its early phase directly stimulates the respiratory centre in the medullary chemoreceptor zone, producing hyperventilation and respiratory alkalosis before the metabolic acidosis of mitochondrial uncoupling becomes dominant. The resulting mixed respiratory alkalosis and metabolic acidosis with anion gap elevation is essentially pathognomonic for salicylate toxicity.

Chapter 4: Drug-Induced Electrolyte Disorders

Drug-Induced Hyponatremia

Hyponatremia — serum sodium below 135 mEq/L — is the most common electrolyte disorder in hospitalized patients and drugs are an important contributing cause. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most frequent drug-induced mechanism, occurring when drugs stimulate ADH release from the posterior pituitary or potentiate ADH action at the collecting duct, causing inappropriate water retention and dilutional hyponatremia.

Drugs that commonly cause SIADH include selective serotonin reuptake inhibitors (SSRIs — the most frequently implicated drug class in drug-induced SIADH, particularly in elderly patients), tricyclic antidepressants, antipsychotics (particularly phenothiazines), carbamazepine, oxcarbazepine, cyclophosphamide, vincristine, NSAIDs, and desmopressin. The clinical presentation of hyponatremia ranges from asymptomatic (discovered on routine laboratory work) through mild symptoms (nausea, malaise, headache) to severe neurological manifestations (confusion, seizures, coma) that reflect cerebral edema from osmotic water movement into brain cells.

Management of drug-induced hyponatremia involves discontinuing the causative agent, fluid restriction in the setting of SIADH (euvolemic or hypervolemic hyponatremia), and cautious correction of sodium. The rate of correction in symptomatic hyponatremia is critically important: overly rapid correction — particularly in patients with chronic hyponatremia — risks osmotic demyelination syndrome (ODS, previously called central pontine myelinolysis), a potentially devastating neurological complication resulting from rapid shrinkage of previously adapted brain cells. The target correction rate is typically 6 to 8 mEq/L per 24 hours, with a maximum of 10 to 12 mEq/L per 24 hours.

Drug-Induced Hypokalemia and Hyperkalemia

Potassium homeostasis — maintaining serum potassium between 3.5 and 5.0 mEq/L — is essential for normal cardiac, neuromuscular, and renal function. Drugs can disturb potassium balance by affecting renal potassium handling, altering the distribution of potassium between intracellular and extracellular compartments, or affecting gastrointestinal potassium intake or loss.

Drug-induced hypokalemia most commonly results from enhanced renal potassium excretion. Loop diuretics (furosemide, ethacrynic acid) and thiazide diuretics (hydrochlorothiazide, chlorthalidone) are the most frequent causes, acting by reducing sodium reabsorption in the thick ascending limb and distal tubule respectively; the resulting increase in distal sodium delivery drives potassium secretion through the principal cells of the collecting duct, mediated by aldosterone activation of luminal potassium channels. The clinical consequences of diuretic-induced hypokalemia include muscle weakness, impaired insulin secretion, increased sensitivity to digoxin toxicity, and ventricular arrhythmias — particularly important in patients with heart failure already at risk of arrhythmia.

Drug-induced hyperkalemia results from impaired renal potassium excretion, shift of potassium out of cells, or excessive exogenous potassium. ACE inhibitors and angiotensin II receptor blockers (ARBs) reduce aldosterone production, decreasing potassium excretion by the collecting duct; the risk is amplified by concurrent use of potassium-sparing diuretics (spironolactone, eplerenone), direct renin inhibitors (aliskiren), NSAIDs (which reduce renal prostaglandin-mediated afferent arteriolar vasodilation, decreasing renal blood flow and GFR), and trimethoprim (which blocks luminal sodium channels in the collecting duct similarly to amiloride). The combination of an ACE inhibitor, an ARB, and a potassium-sparing diuretic (triple RAAS blockade) carries particularly high risk of severe, potentially fatal hyperkalemia and is generally contraindicated.

Chapter 5: Drug-Induced Renal Disorders

Categories of Drug-Induced Nephrotoxicity

The kidney is particularly vulnerable to drug toxicity for several reasons: it receives approximately 20% of cardiac output, concentrating drugs and their metabolites in the tubular fluid; tubular cells perform extensive active transport, accumulating some drugs to concentrations that can cause direct cytotoxicity; and the medullary countercurrent mechanism creates extremely high concentrations of drugs in the inner medulla. Drug-induced nephrotoxicity can affect the glomerulus, the tubules, the tubulointerstitium, or the renal vasculature, producing distinct clinical and pathological syndromes.

Acute tubular necrosis (ATN) is the most common form of drug-induced acute kidney injury (AKI). Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) accumulate in proximal tubular cells through megalin-mediated endocytosis and disrupt lysosomal and mitochondrial function, producing nonoliguric ATN typically emerging after 5 to 10 days of therapy. Risk factors include advanced age, baseline renal impairment, volume depletion, concurrent nephrotoxin exposure, and total cumulative aminoglycoside dose. Extended-interval aminoglycoside dosing (once-daily dosing with a prolonged drug-free interval) exploits the concentration-dependent bactericidal kinetics of aminoglycosides while reducing tubular drug accumulation and nephrotoxicity risk.

Amphotericin B deoxycholate (conventional formulation) causes dose-dependent nephrotoxicity through direct membrane disruption of renal tubular cells and afferent arteriolar vasoconstriction reducing GFR — one of the most nephrotoxic agents in regular clinical use. Lipid formulations of amphotericin B (liposomal amphotericin B, amphotericin B lipid complex) substantially reduce nephrotoxicity while maintaining antifungal activity and are strongly preferred when systemic amphotericin B therapy is indicated.

Contrast-induced nephropathy (CIN, now more precisely termed contrast-associated AKI) occurs in patients receiving iodinated contrast media for radiological procedures, particularly in the setting of baseline CKD, diabetes mellitus, volume depletion, heart failure, and concurrent nephrotoxin use. Prevention strategies include adequate pre-procedure hydration with isotonic saline, minimizing contrast volume, using iso-osmolar or low-osmolar contrast agents, and withholding renally excreted potentially nephrotoxic drugs including metformin, NSAIDs, and ACE inhibitors/ARBs in high-risk patients.

Drug-Induced Glomerulonephritis and Interstitial Nephritis

Acute interstitial nephritis (AIN) is an inflammatory process affecting the renal interstitium and tubules, most commonly mediated by a delayed-type hypersensitivity reaction to a drug. Classic causative agents include penicillins (methicillin was historically associated with AIN; all penicillins carry risk), cephalosporins, NSAIDs, proton pump inhibitors (PPIs — now recognized as one of the most common drug causes of AIN, particularly with long-term use), rifampin, and ciprofloxacin. The classic triad of fever, rash, and eosinophilia — originally described for methicillin-induced AIN — is present in fewer than one-third of cases; AIN caused by NSAIDs and PPIs rarely produces this triad. Diagnosis requires kidney biopsy demonstrating interstitial infiltration by lymphocytes, plasma cells, and eosinophils. Management is drug discontinuation; corticosteroids are sometimes used in severe or persistent cases though definitive evidence for their benefit is limited.

Chapter 6: Drug-Induced Pulmonary Disorders

Mechanisms of Pulmonary Drug Toxicity

The lung is susceptible to drug injury through several mechanisms: direct cytotoxicity to alveolar epithelial cells and vascular endothelium; immune-mediated reactions (hypersensitivity pneumonitis, eosinophilic pneumonia); drug-induced autoimmunity producing lupus-like pulmonary disease; and indirect effects through fluid accumulation (cardiogenic pulmonary edema from cardiotoxic drugs) or central respiratory depression.

Amiodarone pulmonary toxicity is the most important drug-induced pulmonary disorder in clinical pharmacy practice because amiodarone is widely used for cardiac arrhythmia management and has substantial cumulative lung toxicity. Amiodarone is highly lipophilic, accumulates in the lung to concentrations far exceeding plasma levels, and through unclear mechanisms — possibly involving lysosomal phospholipid accumulation and oxidative injury mediated by its desethyl metabolite — produces a spectrum of pulmonary toxicity including acute respiratory distress syndrome, organizing pneumonia (obliterans), diffuse alveolar damage, and more insidiously, chronic interstitial pneumonitis. The cumulative incidence of amiodarone pulmonary toxicity is estimated at 5% to 10% with long-term use, and individual risk correlates with cumulative dose and duration of therapy. Monitoring includes baseline chest X-ray and pulmonary function tests, with annual reassessment; high-resolution CT of the chest is the most sensitive imaging modality for early detection. The only definitive management is discontinuation; given amiodarone’s tissue half-life of 40 to 55 days (approximately 40 to 100 days in some estimates), pulmonary toxicity may persist or worsen for weeks to months after stopping the drug.

Drug-induced bronchospasm is clinically important primarily through three mechanisms. Beta-blockers — including cardioselective beta-1 selective agents — can precipitate bronchospasm in patients with asthma or COPD through antagonism of bronchodilatory beta-2 adrenergic receptors; cardioselective agents carry lower but not negligible risk. Aspirin and NSAIDs precipitate bronchospasm in approximately 5% to 20% of asthmatic patients through inhibition of cyclooxygenase-1, shunting arachidonic acid toward the lipoxygenase pathway, and producing an excess of bronchoconstricting cysteinyl leukotrienes — a condition historically called aspirin-exacerbated respiratory disease (AERD), previously Samter’s triad. ACE inhibitors cause a dry, persistent cough in approximately 10% to 20% of users — not true bronchospasm but a significant cause of medication discontinuation — through accumulation of bradykinin and substance P in the airways as a consequence of ACE inhibitor blockade of the enzyme that normally degrades these peptides. The cough is more prevalent in individuals of East Asian descent, where genetic variants in ACE-related pathways may increase susceptibility.

Chapter 7: Drug-Induced Reproductive Disorders

Teratogenicity and Embryofetal Toxicity

The implications of drug-induced reproductive disorders extend across an enormous temporal range — from acute effects on libido and sexual function through impacts on fertility and gonadal reserve, to the critically important category of teratogenicity affecting the developing embryo and fetus during pregnancy. This section focuses primarily on the mechanisms and clinical significance of drug-induced teratogenicity and on the pharmacist’s role in preventing and detecting drug-induced reproductive harm.

Thalidomide remains the most historically consequential example of drug-induced teratogenicity, producing the embryopathy of limb reduction defects (phocomelia), deafness, facial nerve palsy, and internal organ malformations when taken during gestational weeks 4 through 7 — the critical period for limb bud formation. Thalidomide’s teratogenic mechanism, long incompletely understood, is now thought to involve binding to cereblon (a component of an E3 ubiquitin ligase), leading to degradation of limb bud transcription factors. Paradoxically, thalidomide and its analogs lenalidomide and pomalidomide are now first-line treatments for multiple myeloma and other hematological malignancies; their use in any patient of reproductive potential requires participation in a mandatory risk management program (the Revlimid REMS in the US, a Risk Management Program in Canada).

Valproic acid is an antiepileptic, mood stabilizer, and migraine prophylactic that carries substantial teratogenic risk, causing neural tube defects (risk approximately 2%, compared to 0.1% in the general population), cardiac defects, limb abnormalities, and — most concerning from a functional development perspective — dose-dependent effects on cognitive development manifesting as reduced IQ, autism spectrum disorder, and language delay in children exposed in utero. These neurocognitive effects, unlike structural malformations, may not be apparent until the child reaches school age, and they occur at therapeutic doses. Current guidelines recommend strongly against valproic acid use in people of childbearing potential unless no effective alternative exists, and all patients of reproductive potential receiving valproic acid should be counselled emphatically about the teratogenic risk and offered highly effective contraception.

Drug Effects on Fertility and Sexual Function

Drug-induced sexual dysfunction is vastly underreported because patients are reluctant to raise sexual health concerns with their healthcare providers, and healthcare providers often fail to ask. The prevalence of sexual dysfunction among patients taking drugs known to affect sexual function is substantial: estimates suggest that 30% to 70% of patients taking serotonergic antidepressants (SSRIs, SNRIs) experience some form of sexual dysfunction, most commonly delayed or absent orgasm, reduced libido, or delayed ejaculation. The mechanism involves serotonin-mediated inhibition of dopaminergic pathways in the hypothalamus that normally facilitate sexual arousal and response, and peripheral serotonin effects on genital neurovascular function.

Antipsychotics cause sexual dysfunction through multiple mechanisms including dopamine blockade in the tuberoinfundibular pathway, raising prolactin levels (hyperprolactinemia suppresses gonadotropin-releasing hormone pulsatility and gonadotropin secretion, reducing testosterone and estrogen); antihistaminic and anticholinergic effects impairing arousal; and alpha-1 adrenergic blockade impairing ejaculation. Prolactin elevation with antipsychotics varies by agent: risperidone and paliperidone (which do not cross the blood-brain barrier from the periphery as freely as other dopamine antagonists reach the pituitary, which is outside the blood-brain barrier) produce the highest prolactin levels; clozapine and quetiapine produce little or no prolactin elevation; olanzapine and aripiprazole fall between.

Chapter 8: Drug-Induced Gastrointestinal Disorders

Drug-Induced Upper Gastrointestinal Injury

NSAID-associated gastrointestinal toxicity is one of the most clinically important and extensively studied drug-induced diseases, estimated to cause tens of thousands of hospitalizations and thousands of deaths annually in North America. NSAIDs damage the gastrointestinal mucosa through two mechanisms. The topical effect — NSAIDs are weak acids that accumulate in gastric mucosal cells and disrupt the hydrophobic surface lipid layer, uncoupling oxidative phosphorylation and causing mitochondrial damage — is largely responsible for mucosal erosions and lesions, particularly in the stomach. The systemic effect — inhibition of cyclooxygenase-1 and consequent reduction in prostaglandin E₂ and I₂ synthesis in the gastric mucosa — reduces mucus secretion, bicarbonate secretion, and mucosal blood flow, compromising the cytoprotective mechanisms of the gastric mucosa.

Risk factors for NSAID-induced GI complications include advanced age (> 65), prior history of peptic ulcer disease or GI bleeding, concurrent anticoagulant or corticosteroid use, Helicobacter pylori infection, and high-dose or multiple NSAID use. Risk stratification guides the co-prescription of proton pump inhibitors (PPIs), which are recommended for all patients with high GI risk who require NSAID therapy. Selective COX-2 inhibitors (celecoxib) reduce GI toxicity by approximately 50% relative to non-selective NSAIDs, though they carry cardiovascular risks through inhibition of prostacyclin-mediated vasodilation without the counterbalancing reduction in thromboxane A₂ that comes from platelet COX-1 inhibition.

Drug-induced hepatotoxicity (DILI — drug-induced liver injury) encompasses a spectrum from asymptomatic transaminase elevations to acute liver failure. It is classified as intrinsic (dose-dependent, predictable — as with acetaminophen) or idiosyncratic (dose-independent, unpredictable). Acetaminophen hepatotoxicity is the leading cause of acute liver failure in North America. At therapeutic doses (< 4 g/day in adults), acetaminophen is metabolized primarily by glucuronidation and sulfation; a small fraction undergoes CYP2E1-mediated oxidation to N-acetyl-p-benzoquinone imine (NAPQI), which is rapidly conjugated with glutathione and excreted harmlessly. In overdose — or in patients with reduced glucuronidation capacity (starvation, alcoholism), increased CYP2E1 activity (chronic ethanol use, fasting, rifampin), or depleted glutathione stores — NAPQI accumulates, binds covalently to cellular proteins, and causes mitochondrial dysfunction and hepatocyte necrosis. Treatment with N-acetylcysteine (NAC), a glutathione precursor, is highly effective when administered within 8 to 10 hours of ingestion and retains some benefit up to 24 hours; it should be initiated based on the Rumack-Matthew nomogram in acute ingestion or empirically in late-presenting patients with elevated transaminases.

Chapter 9: Drug-Induced Bone, Muscle, and Skin Disorders

Drug-Induced Osteoporosis

Long-term corticosteroid use is the most common cause of secondary osteoporosis. Glucocorticoid-induced osteoporosis (GIOP) results from multiple mechanisms: direct inhibition of osteoblast differentiation and function (reduced bone formation), stimulation of osteoclastogenesis through RANKL upregulation (increased bone resorption), inhibition of intestinal calcium absorption, and increased urinary calcium excretion through renal tubular effects. The resulting bone loss is most rapid in the first 3 to 6 months of treatment, and the skeleton’s trabecular compartment (most metabolically active bone, predominating in the spine and femoral neck) is preferentially affected, explaining the characteristic predisposition of GIOP for vertebral and hip fractures.

Fracture risk assessment using the FRAX tool (Fracture Risk Assessment) and clinical risk factor evaluation guides decisions about pharmacological fracture prevention. Canadian guidelines recommend bone-protective therapy (bisphosphonates as first-line, denosumab as an alternative) for patients receiving glucocorticoids at doses of 7.5 mg prednisone equivalent or greater per day for 3 months or longer who have moderate to high fracture risk. Calcium and vitamin D supplementation are recommended for all patients on chronic glucocorticoid therapy.

Drug-Induced Myopathy

Skeletal muscle toxicity from drugs spans a spectrum from asymptomatic creatine kinase (CK) elevation through mild myalgia to severe rhabdomyolysis — massive muscle fiber breakdown that releases myoglobin into the circulation, causing renal tubular obstruction and ischemia that can produce acute kidney injury.

Statin-induced myopathy is clinically the most significant form of drug-induced muscle disease because statins are among the most widely prescribed drugs globally. Myalgia (muscle pain or weakness without CK elevation) occurs in approximately 5% to 10% of statin users in clinical practice (though lower rates are observed in randomized trials, suggesting that some myalgia attributed to statins may not be causally related). CK elevation above 10 times the upper limit of normal with symptoms defines clinically significant myositis; rhabdomyolysis — severe CK elevation (typically > 40 times normal), myoglobinuria, and acute kidney injury — occurs in approximately 1 in 10,000 statin users. Risk factors for statin myopathy include high-dose statins, advanced age, female sex, low body mass index, hypothyroidism, chronic kidney disease, and concurrent use of CYP3A4 inhibitors that raise plasma statin concentrations (clarithromycin, itraconazole, cyclosporine, amiodarone).

Drug-Induced Skin Disorders

The skin is the organ most frequently involved in adverse drug reactions, with dermatological manifestations occurring in an estimated 2% to 3% of all hospitalized patients receiving drug therapy. The spectrum ranges from mild, transient maculopapular exanthems to the potentially fatal Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

SJS/TEN represents a spectrum of severe cutaneous adverse reactions characterized by widespread epidermal detachment and necrosis. SJS is defined by skin detachment affecting less than 10% of body surface area; TEN by detachment of more than 30%; SJS-TEN overlap syndrome involves 10% to 30%. The mortality of TEN approaches 30% to 40% and is predicted by the SCORTEN severity score. The pathophysiology involves drug or drug-reactive metabolite haptenization of HLA class I-associated peptides, triggering cytotoxic T-cell-mediated keratinocyte apoptosis. Pharmacogenomic associations have been established for several high-risk drug-HLA combinations: carbamazepine-SJS is strongly associated with HLA-B15:02 (prevalent in individuals of Han Chinese, Thai, and other Southeast Asian descent); allopurinol-SJS/TEN is associated with HLA-B58:01 (prevalent in East Asian populations); and abacavir hypersensitivity syndrome is associated with HLA-B*57:01 (prevalent in white Europeans). Prospective HLA screening before prescribing carbamazepine in at-risk populations is recommended by regulatory agencies in multiple jurisdictions including Health Canada.

Chapter 10: Drug-Induced Endocrine Disorders

Drug-Induced Diabetes Mellitus

Multiple drug classes can impair glucose homeostasis, producing new-onset diabetes or worsening glycemic control in patients with pre-existing diabetes mellitus. Corticosteroids produce dose-dependent insulin resistance through inhibition of GLUT4 translocation in skeletal muscle (reducing peripheral glucose uptake), stimulation of hepatic gluconeogenesis, and — at high doses — impairment of pancreatic beta-cell insulin secretion. The resulting hyperglycemia, termed steroid-induced diabetes, may be transient (resolving when steroids are discontinued) or may unmask underlying latent type 2 diabetes that persists. Glucocorticoid-induced hyperglycemia characteristically peaks in the afternoon and evening, corresponding to the pharmacodynamic peak of morning-administered prednisone, and is often initially controlled with intermediate-acting insulins (NPH) timed to address this pattern.

Antipsychotic-induced metabolic syndrome — the constellation of weight gain, dyslipidemia, hyperglycemia, and hypertension — is a major public health concern given the widespread use of second-generation (atypical) antipsychotics. The metabolic liability of antipsychotics varies substantially by agent: clozapine and olanzapine carry the greatest risk, followed by quetiapine and risperidone; aripiprazole and ziprasidone carry the lowest metabolic risk. Mechanisms include histamine H1 receptor blockade (promoting weight gain through appetite stimulation and altered satiety signalling), muscarinic M3 receptor blockade in pancreatic beta cells (impairing insulin secretion), and direct effects on adipose tissue metabolism.

Drug-Induced Thyroid Disorders

Amiodarone has complex effects on thyroid function arising from its high iodine content (approximately 37% by weight, with each 200 mg tablet releasing approximately 75 mg of free iodine — roughly 50 times the daily iodine requirement), its structural similarity to thyroid hormones, and its direct effects on thyroid hormone metabolism. Amiodarone inhibits the peripheral deiodination of thyroxine (T₄) to the active triiodothyronine (T₃) through inhibition of type I and type II deiodinase, causing characteristic changes in thyroid function tests: elevated T₄, reduced T₃, elevated reverse T₃ (the inactive isomer), and a transient early rise in TSH, all of which occur in virtually all patients on amiodarone and are expected — not pathological — consequences of normal amiodarone pharmacology.

Thyroid dysfunction occurs in approximately 14% to 18% of patients on long-term amiodarone: amiodarone-induced hypothyroidism (AIH) occurs more commonly in iodine-sufficient populations through the Wolff-Chaikoff effect (excess iodide suppresses thyroid hormone synthesis in normal glands, but most individuals escape this inhibition within weeks; those with underlying autoimmune thyroid disease or chronically treated hypothyroidism cannot escape, producing sustained hypothyroidism). Amiodarone-induced thyrotoxicosis (AIT) occurs more commonly in iodine-deficient populations and takes two forms: AIT type 1 (excess iodide drives increased thyroid hormone synthesis in an autonomous or goitrousthyroid gland — treated with thionamides) and AIT type 2 (destructive thyroiditis from direct amiodarone toxicity releasing preformed thyroid hormone — treated with glucocorticoids). Because amiodarone cannot be discontinued in many patients without life-threatening arrhythmia recurrence, thyroid monitoring and management must proceed while continuing the drug.

Chapter 11: Drug-Induced Psychiatric Disorders

Drug-Induced Depression and Psychosis

The central nervous system, with its enormous pharmacological complexity and sensitivity, is a frequent site of drug-induced pathology. Drug-induced psychiatric disorders are particularly challenging to recognize because psychiatric symptoms are common in the general population, often pre-existing in the patients who receive drugs most likely to cause CNS effects, and difficult to attribute definitively to a drug without a clear temporal relationship to initiation or discontinuation.

Drug-induced depression may arise through various mechanisms. Interferon-alpha — used in the treatment of hepatitis C and certain malignancies — produces depression in approximately 20% to 30% of patients, through pro-inflammatory cytokine-mediated alterations in serotonin, dopamine, and norepinephrine metabolism and neuroinflammatory effects on the prefrontal cortex. The depression is sufficiently severe in some cases to require antidepressant pre-treatment before initiation of interferon therapy or early intervention with SSRIs during therapy. Corticosteroids produce mood disturbances in up to 57% of patients, with a paradoxical biphasic pattern — early treatment often produces euphoria and hypomania, while prolonged or high-dose treatment may produce depression, emotional lability, and in severe cases, steroid psychosis. Isotretinoin — the highly teratogenic retinoid used for severe acne — carries regulatory labelling warnings about depression and suicidality, though evidence from large pharmacoepidemiological studies has not established a causal relationship with certainty.

Drug-induced psychosis can result from dopaminergic excess (levodopa, dopamine agonists used in Parkinson’s disease, corticosteroids), NMDA receptor antagonism at supratherapeutic levels (ketamine, phencyclidine), or cholinergic deficiency (anticholinergic toxidrome from opioids in neonates, tricyclic antidepressants, antihistamines, antiparkinsonian agents). Levodopa-induced psychosis in Parkinson’s disease — typically manifesting as vivid visual hallucinations (often benign, well-formed images of people or animals) that may progress to paranoid delusions in severe cases — is managed by stepwise reduction of the dopaminergic regimen (removing monoamine oxidase inhibitors, anticholinergics, amantadine, and dopamine agonists before cautiously reducing levodopa itself) and, if pharmacological treatment is required, pimavanserin (a selective serotonin 5-HT2A inverse agonist) — the first FDA-approved treatment specifically for Parkinson’s disease psychosis — or clozapine at very low doses.

Drug-Induced Cognitive Impairment

Medications with anticholinergic properties produce measurable cognitive impairment — impaired attention, working memory, and processing speed — in older adults, and chronic exposure to anticholinergic drugs has been associated in pharmacoepidemiological studies with increased risk of dementia. The anticholinergic burden concept quantifies the cumulative anticholinergic activity of a patient’s medication regimen; tools such as the Anticholinergic Cognitive Burden (ACB) scale and Anticholinergic Risk Scale (ARS) rank commonly prescribed drugs by their anticholinergic activity to guide deprescribing decisions in older adults.

Drugs with high anticholinergic activity include first-generation antihistamines (diphenhydramine, chlorpheniramine), tricyclic antidepressants (amitriptyline, nortriptyline, imipramine), bladder antimuscarinics (oxybutynin, tolterodine — though newer agents such as solifenacin and mirabegron have lower CNS anticholinergic activity), antiparkinsonian anticholinergics (trihexyphenidyl, benztropine), and antipsychotics (clozapine, olanzapine). Pharmacist-led medication reviews that identify and address high anticholinergic burden through substitution with less anticholinergic alternatives are among the most evidence-supported deprescribing interventions in geriatric pharmacy practice.

Chapter 12: Drug-Induced Cardiovascular Disorders

Drug-Induced Cardiac Arrhythmias

The QT interval on the surface electrocardiogram reflects the duration of ventricular repolarization and corresponds to the combined duration of the action potential plateau (phase 2) and repolarization (phase 3). Prolongation of the QT interval beyond 450 ms in males and 470 ms in females (or, practically, beyond approximately 500 ms by any standard) is associated with increased risk of torsades de pointes (TdP) — a polymorphic ventricular tachycardia with the characteristic oscillation of QRS axis around the isoelectric line — which may degenerate into ventricular fibrillation and sudden cardiac death.

Numerous drugs prolong the QT interval by blocking the cardiac rapid delayed rectifier potassium current (IKr), mediated by the hERG channel, which is responsible for phase 3 repolarization. Offending drug classes include antiarrhythmics (quinidine, amiodarone, sotalol, dofetilide), antipsychotics (haloperidol, thioridazine, ziprasidone, clozapine), antidepressants (tricyclics, citalopram/escitalopram at high doses), antibiotics (azithromycin, ciprofloxacin, clarithromycin), antiemetics (ondansetron, metoclopramide — particularly at intravenous doses), antihistamines (terfenadine and astemizole were withdrawn from market because of fatal arrhythmias; currently available antihistamines have much lower TdP risk), and antimalarials (chloroquine, halofantrine). Additive risk occurs with drug combinations that individually prolong the QT interval. The CredibleMeds QTDrugs database (https://www.crediblemeds.org) maintained by the Arizona CERT provides an authoritative, regularly updated risk classification for drug-associated TdP.

Drug-induced heart failure can arise from cardiomyopathy caused by direct myocardial toxicity. Anthracycline cardiomyopathy — caused by the anthracycline chemotherapy agents doxorubicin, daunorubicin, epirubicin, and idarubicin — is the best characterized chemotherapy-induced cardiac toxicity. Anthracyclines generate reactive oxygen species through redox cycling and form cardiotoxic complexes with the iron-containing topoisomerase II beta, producing mitochondrial dysfunction and cardiomyocyte apoptosis. The risk of anthracycline-induced cardiomyopathy is dose-dependent — traditionally minimal below cumulative doxorubicin doses of 300 mg/m² and rising steeply above 450 mg/m² — but individual susceptibility varies substantially, and more recent data suggest cardiotoxicity can occur at any cumulative dose, particularly in older patients and those with pre-existing cardiovascular risk factors. Dexrazoxane, an iron chelator that competes with anthracyclines for topoisomerase II beta binding, is approved for cardioprotection in patients who have already received a significant cumulative anthracycline dose; its use in breast cancer is most firmly supported by evidence. Longitudinal cardiac function monitoring with echocardiography or MUGA scanning is recommended for all patients receiving cardiotoxic chemotherapy regimens.

Drug-Induced Hypertension

Multiple drug classes raise blood pressure through various mechanisms. NSAIDs increase blood pressure by inhibiting prostaglandin-mediated vasodilation and renal prostaglandin E₂-dependent natriuresis, leading to sodium and water retention; they also blunt the efficacy of most antihypertensive drug classes. Sympathomimetics — including decongestants containing pseudoephedrine or phenylephrine, weight loss medications containing phentermine, and stimulants — raise blood pressure and heart rate through alpha-1 and/or beta-1 adrenergic receptor activation. Oral contraceptives containing estrogen raise blood pressure in approximately 5% of users through multiple mechanisms including activation of the renin-angiotensin-aldosterone system; progestogen-only contraceptives have minimal effect on blood pressure. Erythropoiesis-stimulating agents (EPO, darbepoetin) cause hypertension in a substantial proportion of patients with chronic kidney disease and cancer through increased blood viscosity (from rising hematocrit), direct vasoconstriction, and endothelin upregulation.

Pharmacist-led medication review to identify and address drug-induced hypertension is a high-yield clinical activity in patients whose blood pressure is inadequately controlled despite optimal antihypertensive therapy. Quantifying the blood pressure-raising contribution of specific medications, identifying opportunities for substitution or dose reduction, and monitoring blood pressure response to medication changes exemplify the kind of systematic pharmacist intervention that directly benefits patient outcomes in this common and consequential drug-induced condition.